- Home
- EVGO vs TNGX Comparison
EVGO vs TNGX Comparison
Compare EVGO & TNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EVGO
- TNGX
- Stock Information
- Founded
- EVGO 2010
- TNGX 2014
- Country
- EVGO United States
- TNGX United States
- Employees
- EVGO N/A
- TNGX N/A
- Industry
- EVGO Other Specialty Stores
- TNGX Biotechnology: Pharmaceutical Preparations
- Sector
- EVGO Consumer Discretionary
- TNGX Health Care
- Exchange
- EVGO Nasdaq
- TNGX Nasdaq
- Market Cap
- EVGO 376.5M
- TNGX 351.2M
- IPO Year
- EVGO N/A
- TNGX N/A
- Fundamental
- Price
- EVGO $3.50
- TNGX $6.13
- Analyst Decision
- EVGO Strong Buy
- TNGX Strong Buy
- Analyst Count
- EVGO 10
- TNGX 6
- Target Price
- EVGO $6.00
- TNGX $12.20
- AVG Volume (30 Days)
- EVGO 4.8M
- TNGX 2.7M
- Earning Date
- EVGO 07-31-2025
- TNGX 08-06-2025
- Dividend Yield
- EVGO N/A
- TNGX N/A
- EPS Growth
- EVGO N/A
- TNGX N/A
- EPS
- EVGO N/A
- TNGX N/A
- Revenue
- EVGO $276,954,000.00
- TNGX $40,990,000.00
- Revenue This Year
- EVGO $41.18
- TNGX N/A
- Revenue Next Year
- EVGO $33.63
- TNGX N/A
- P/E Ratio
- EVGO N/A
- TNGX N/A
- Revenue Growth
- EVGO 45.15
- TNGX 10.09
- 52 Week Low
- EVGO $2.20
- TNGX $1.03
- 52 Week High
- EVGO $9.07
- TNGX $12.02
- Technical
- Relative Strength Index (RSI)
- EVGO 39.61
- TNGX 71.70
- Support Level
- EVGO $3.27
- TNGX $5.75
- Resistance Level
- EVGO $3.59
- TNGX $6.40
- Average True Range (ATR)
- EVGO 0.23
- TNGX 0.48
- MACD
- EVGO -0.07
- TNGX -0.04
- Stochastic Oscillator
- EVGO 11.79
- TNGX 75.62
About EVGO EVgo Inc.
EVgo owns and operates a public direct current fast-charging network in the US. Its network of charging stations provides electric vehicle charging infrastructure to consumers and businesses. The network is capable of charging all EV models and meets all charging standards currently available in the US. EVgo partners with national and regional chains of grocery stores, automotive original equipment manufacturers, hotels, shopping centers, gas stations, parking lot operators, local governments, and independent property owners to locate and deploy its EV charging infrastructure.
About TNGX Tango Therapeutics Inc.
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.